Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2003

View Archived Issues

Company Profile: Sirus Pharmaceuticals

Local analgesic effects described for tricyclic antidepressants in rats

Aripiprazole is safe and effective in the treatment of schizophrenia and schizoaffective disorders

Hemispherx enters research agreement with Johann Wolfgang Goethe U. Hospital

Alzheimer's vaccine goal of new collaboration

AIDS Healthcare Foundation to urge FDA to withdraw Trizivir approval

OvuLook saliva-based ovulation system launched

Generex completes Antigen Express acquisition

Transkaryotic Therapies retakes Factor VIII gene therapy rights from Wyeth

Santen seeks Japanese manufacturing approval for vernal keratoconjunctivitis treatment

Elite authorizes merger negotiations with Nostrum

Titan updates key program status

New, potent inhibitors of rat 17alpha-hydroxylase/C17,20-lyase

Potent and selective non-imidazole human histamine H4 receptor antagonists

Affimed and Dyax enter crosslicensing agreement for phage display technologies

Merck KGaA acquires ProteoPlex

Novel nAchR ligands under study at Sanofi-Synthelabo

Acadia patent covers new muscarinic agonists with utility in cognition disorders

Novel 5-HT2A receptor inverse agonists evaluated by Acadia scientists

New beta-secretase inhibitors identified by Elan and Pharmacia team

Novel 5-HT2C receptor ligands and their use in depression and anxiety

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026